• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆管癌患者的生存情况及决策概述

Survival and an overview of decision-making in patients with cholangiocarcinoma.

作者信息

Forsmo Havard Mjorud, Horn Arild, Viste Asgaut, Hoem Dag, Ovrebo Kjell

机构信息

Department of Surgery, Haukeland University Hospital, Bergen, Norway.

出版信息

Hepatobiliary Pancreat Dis Int. 2008 Aug;7(4):412-7.

PMID:18693178
Abstract

BACKGROUND

Cholangiocarcinoma is rare, accounting for approximately 3% of all gastrointestinal cancers. This study aimed to identify the survival rate among surgically treated and palliated patients, and secondly to identify parameters that could predict a curative resection.

METHODS

A total of 121 patients, 55 men and 66 women, median age 70 years (range 31-91), who had been treated for cholangiocarcinoma in the period of 1990-2005 were evaluated retrospectively.

RESULTS

Curative resection was performed in 40 patients (33%), whereas 81 received palliative treatment (67%). 16% (19 of 121) of the patients had an explorative laparotomy without tumour resection. Age above 65 years (OR 3.4; 95% CI 1.4-8.4; P=0.008), weight loss (OR 8.5; 95% CI 1.5-46; P=0.01) or tumour location (The resection rate of hilar cholangiocarcinoma was lower than that of intrapancreatic cancer.) (OR 2.7; 95% CI 1.7-4.5; P=0.001) predicted palliative treatment. The adjusted 5-year survival rate of patients who received tumour resection and palliative treatment was 30% and 1.2 %, respectively (P<0.001). The survival rate of patients who were subjected to hepatectomy (70%) was better than that of patients who had a local or distal resection (20%) (P=0.02).

CONCLUSIONS

In few patients with a resectable cholangiocarcinoma, an explorative laparotomy is often necessary to evaluate resectability. However, long-term survival is significantly better in patients who received radical surgical resection.

摘要

背景

胆管癌较为罕见,约占所有胃肠道癌症的3%。本研究旨在确定接受手术治疗和姑息治疗患者的生存率,其次是确定可预测根治性切除的参数。

方法

回顾性评估了1990年至2005年期间接受胆管癌治疗的121例患者,其中男性55例,女性66例,中位年龄70岁(范围31 - 91岁)。

结果

40例患者(33%)接受了根治性切除,而81例接受了姑息治疗(67%)。16%(121例中的19例)患者进行了探查性剖腹手术但未进行肿瘤切除。65岁以上(比值比3.4;95%置信区间1.4 - 8.4;P = 0.008)、体重减轻(比值比8.5;95%置信区间1.5 - 46;P = 0.01)或肿瘤位置(肝门部胆管癌的切除率低于胰内癌)(比值比2.7;95%置信区间1.7 - 4.5;P = 0.001)可预测姑息治疗。接受肿瘤切除和姑息治疗患者的调整后5年生存率分别为30%和1.2%(P < 0.001)。接受肝切除术患者的生存率(70%)优于进行局部或远端切除术患者的生存率(20%)(P = 0.02)。

结论

在少数可切除的胆管癌患者中,通常需要进行探查性剖腹手术以评估可切除性。然而,接受根治性手术切除的患者长期生存率明显更高。

相似文献

1
Survival and an overview of decision-making in patients with cholangiocarcinoma.胆管癌患者的生存情况及决策概述
Hepatobiliary Pancreat Dis Int. 2008 Aug;7(4):412-7.
2
Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence.肝门部胆管癌切除术:同期肝切除可降低肝内复发率。
Ann Surg. 2008 Aug;248(2):273-9. doi: 10.1097/SLA.0b013e31817f2bfd.
3
Surgical procedure and prognosis of hilar cholangiocarcinoma.肝门部胆管癌的手术治疗及预后
Hepatobiliary Pancreat Dis Int. 2004 Aug;3(3):453-7.
4
[Aggressive surgical treatment for cholangiocarcinoma].
Harefuah. 2001 Jun;140(6):479-82, 566.
5
Surgical therapy for hiliar cholangiocarcinoma: analysis of 198 cases.肝门部胆管癌的手术治疗:198例分析
Hepatobiliary Pancreat Dis Int. 2006 May;5(2):278-82.
6
Aggressive surgical resection for hilar cholangiocarcinoma.肝门部胆管癌的积极手术切除
ANZ J Surg. 2005 Nov;75(11):981-5. doi: 10.1111/j.1445-2197.2005.03595.x.
7
Surgical treatment of mass-forming intrahepatic cholangiocarcinoma: an 11-year Western single-center experience in 107 patients.肿块型肝内胆管癌的外科治疗:一项针对107例患者的11年西方单中心经验。
Ann Surg Oncol. 2009 Feb;16(2):404-12. doi: 10.1245/s10434-008-0227-1. Epub 2008 Nov 27.
8
Changing trends in surgical outcomes after major hepatobiliary resection for hilar cholangiocarcinoma: a single-center experience over 25 years.肝门部胆管癌大肝胆切除术后手术结果的变化趋势:一项25年的单中心经验
J Hepatobiliary Pancreat Surg. 2007;14(5):455-62. doi: 10.1007/s00534-006-1194-1. Epub 2007 Sep 28.
9
[Experience in resection of hilar cholangiocarcinoma: a report of 54 cases].肝门部胆管癌切除术的经验:附54例报告
Zhonghua Wai Ke Za Zhi. 2006 Apr 1;44(7):441-4.
10
Surgical approach to bismuth Type I and II hilar cholangiocarcinomas: audit of 54 consecutive cases.针对比氏I型和II型肝门部胆管癌的手术方法:对54例连续病例的审计
Ann Surg. 2007 Dec;246(6):1052-7. doi: 10.1097/SLA.0b013e318142d97e.

引用本文的文献

1
Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review.立体定向体部放射治疗在胆管癌中的应用:一项系统评价
Br J Radiol. 2019 May;92(1097):20180688. doi: 10.1259/bjr.20180688. Epub 2019 Feb 7.
2
Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma.立体定向体部放射治疗用于肝内和肝门部胆管癌
J Cancer. 2015 Aug 1;6(11):1099-104. doi: 10.7150/jca.13032. eCollection 2015.
3
Prognostic factors following surgical resection of distal bile duct cancer.远端胆管癌手术切除后的预后因素
J Korean Surg Soc. 2013 Nov;85(5):212-8. doi: 10.4174/jkss.2013.85.5.212. Epub 2013 Oct 25.
4
[Klatskin tumors: rational diagnostics and staging].[肝门部胆管癌:合理的诊断与分期]
Chirurg. 2012 Mar;83(3):215-20. doi: 10.1007/s00104-011-2176-7.
5
Surgical resection for hilar cholangiocarcinoma: experience improves resectability.肝门部胆管癌的外科切除术:经验可提高可切除性。
HPB (Oxford). 2012 Feb;14(2):142-9. doi: 10.1111/j.1477-2574.2011.00419.x. Epub 2011 Dec 12.
6
Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis.血清糖类抗原(CA)19-9作为胆管癌预后因素的Meta分析
Front Med China. 2010 Dec;4(4):457-62. doi: 10.1007/s11684-010-0240-1. Epub 2010 Nov 16.
7
Multimodal oncological therapy comprising stents, brachytherapy, and regional chemotherapy for cholangiocarcinoma.多模态肿瘤治疗包括胆管癌支架、近距离放疗和区域化疗。
Gut Liver. 2010 Sep;4 Suppl 1(Suppl 1):S82-8. doi: 10.5009/gnl.2010.4.S1.S82. Epub 2010 Sep 10.
8
Cholangiocarcinoma: new insights into disease pathogenesis and biology.胆管癌:对疾病发病机制和生物学特性的新认识。
Infect Dis Clin North Am. 2010 Dec;24(4):871-84, vii. doi: 10.1016/j.idc.2010.07.006.
9
Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma.合并症会对肝外胆管癌患者的预后产生负面影响。
World J Gastroenterol. 2009 Nov 14;15(42):5279-86. doi: 10.3748/wjg.15.5279.
10
Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.胆管癌诊断、治疗与姑息治疗的进展:1990 - 2009年
World J Gastroenterol. 2009 Sep 14;15(34):4240-62. doi: 10.3748/wjg.15.4240.